<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03873545</url>
  </required_header>
  <id_info>
    <org_study_id>PRO-002</org_study_id>
    <nct_id>NCT03873545</nct_id>
  </id_info>
  <brief_title>Prospective Evaluation of ProChondrix CR for Repair of Articular Cartilage Defects on Femoral Condyle and Patella</brief_title>
  <official_title>A Prospective, Multi-Center Study Evaluating ProChondrix® CR for the Repair of Focal Articular Cartilage Defects in the Knee</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>AlloSource</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>AlloSource</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this clinical study is to evaluate the use of ProChondrix Cryopreserved&#xD;
      Osteochondral Allograft to obtain evidence of effectiveness, defined as an improvement in&#xD;
      physical function and pain, when used on a symptomatic cartilage defect on the femoral&#xD;
      condyle or patella in a mechanically stable knee.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This clinical study will use a multi-center, prospective design, to evaluate ProChondrix CR&#xD;
      in approximately 80 patients who are scheduled to undergo treatment of a cartilage defect on&#xD;
      the femoral condyle or patella.Patient follow-up will include a period of 60 months after&#xD;
      surgery. During this follow-up period, each patient will be evaluated seven (7) times at: 3,&#xD;
      6, 12, 24, 36, 48 and 60 months after surgical intervention.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">March 18, 2019</start_date>
  <completion_date type="Anticipated">December 30, 2026</completion_date>
  <primary_completion_date type="Anticipated">April 1, 2026</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Subjective International Knee Documentation Committee (IKDC) Score</measure>
    <time_frame>Baseline, 3, 6, 12, 24, 36, 48 and 60 months</time_frame>
    <description>Change in physical pain and function as assessed by IKDC score from baseline to 60 months post-surgery</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Knee injury and Osteoarthritis Outcome Score (KOOS)</measure>
    <time_frame>Baseline, 3, 6, 12, 24, 36, 48 and 60 months</time_frame>
    <description>Change of physical pain as assessed by KOOS score from baseline to 60 months post-surgery</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>SF-12 survey</measure>
    <time_frame>Baseline, 3, 6, 12, 24, 36, 48 and 60 months</time_frame>
    <description>Change in functional health and well-being as assessed by SF-12 survey from baseline to 60 months post-surgery</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Magnetic Resonance Observation of Cartilage Repair Tissue (MOCART) Scores</measure>
    <time_frame>12, 24 and 60 months</time_frame>
    <description>Assessment of repair cartilage structure</description>
  </secondary_outcome>
  <enrollment type="Anticipated">80</enrollment>
  <condition>Cartilage Injury</condition>
  <condition>Cartilage Damage</condition>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Cryopreserved Osteochondral Allograft</intervention_name>
    <description>This tissue is a laser-etched, cryopreserved fresh osteochondral allograft that was developed as a single-stage alternative for articular cartilage restoration.</description>
    <other_name>ProChondrix CR</other_name>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Skeletally mature patients between the ages of ≥18 and ≤ 60 who have a symptomatic&#xD;
        cartilage defect (Grade 3 or 4) on the femoral condyle or patella, in a mechanically stable&#xD;
        knee, or is being mechanically stabilized in the same procedure, between ≥ 1 cm2 and ≤ 5&#xD;
        cm2, measured as a rectangle length x width, as confirmed by MRI or arthroscopy.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Patient is ≥18 and ≤ 60 years old at the time of surgery;&#xD;
&#xD;
          -  Symptomatic patient presenting with moderate to severe pain in the index knee -&#xD;
             unresponsive to conservative treatment (i.e. medication, bracing, physical therapy)&#xD;
             and/or previous surgical intervention;&#xD;
&#xD;
          -  Radiographically diagnosed, by MRI, or through arthroscopy, to have a cartilage defect&#xD;
             on the femoral condyle or patella between ≥ 1 cm2 and ≤ 5 cm2, measured as a rectangle&#xD;
             length x width;&#xD;
&#xD;
          -  Will be having a marrow stimulation plus ProChondrix CR procedure;&#xD;
&#xD;
          -  Has an intact meniscus (maximum of ≤50% resected);&#xD;
&#xD;
          -  Have the ability to understand the requirements of the study, to provide written&#xD;
             informed consent, and to comply with the study protocol.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Has &gt; 5° of varus or valgus deformity;&#xD;
&#xD;
          -  Bipolar articular cartilage involvement (kissing lesions) of the ipsilateral&#xD;
             compartment (i.e. &gt; than ICRS Grade 2 on the opposing articular surface);&#xD;
&#xD;
          -  Associated damage to the underlying subchondral bone &gt;2 mm requiring osseous repair;&#xD;
&#xD;
          -  Requires concomitant ligament repair other than Anterior Cruciate Ligament (ACL) or&#xD;
             Medial Patella-Femoral Ligament (MPFL) reconstruction;&#xD;
&#xD;
          -  Body Mass Index (BMI)of ≥ 35 kg/m2;&#xD;
&#xD;
          -  Active malignancy: undergoing treatment for tumor or boney traumatic injury or a&#xD;
             history of any invasive malignancy (except non-melanoma skin cancer), unless the&#xD;
             patient has been treated with curative intent and there have been no clinical signs or&#xD;
             symptoms of the malignancy for at least 5 years;&#xD;
&#xD;
          -  Clinical and/or radiographic disease in the affected joint that includes:&#xD;
             osteoarthritis or avascular necrosis, gout or a history of gout or pseudogout,&#xD;
             osteochondritis dissecans with significant bone loss;&#xD;
&#xD;
          -  Cartilage lesion location such that the implanted graft will not be adequately&#xD;
             shouldered;&#xD;
&#xD;
          -  Active local microbial infection or a systemic infection, including prior or pending&#xD;
             treatment for HIV, syphilis, Hepatitis B or Hepatitis C;&#xD;
&#xD;
          -  Currently immunologically suppressed or immunocompromised, or a medical condition&#xD;
             requiring radiation, chemotherapy or immunosuppression;&#xD;
&#xD;
          -  Unstable cardiovascular, renal, hepatic, endocrine and/or pulmonary disease, cancer or&#xD;
             uncontrolled diabetes;&#xD;
&#xD;
          -  Has a history of any inflammatory or connective tissue disease, such as, systemic&#xD;
             lupus erythematosus (SLE), Addison's disease, Crohn's disease, multiple sclerosis,&#xD;
             polychondritis or rheumatoid arthritis;&#xD;
&#xD;
          -  Received hyaluronic acid injections into the joint space ≤ 90 days prior to surgery;&#xD;
&#xD;
          -  Is a female patient who is pregnant;&#xD;
&#xD;
          -  Physically or mentally compromised (i.e. being currently treated for a psychiatric&#xD;
             disorder, senile dementia, Alzheimer's disease) in a manner that would compromise&#xD;
             his/her ability to participate in the clinical study;&#xD;
&#xD;
          -  Has a history of substance abuse (recreational drugs, alcohol) or has been treated in&#xD;
             the last 6 months before enrollment for alcohol and/or drug abuse in an in-patient&#xD;
             substance abuse program;&#xD;
&#xD;
          -  Patients who, in the opinion of the Investigator, would not be able or willing to&#xD;
             comply with the protocol;&#xD;
&#xD;
          -  Is currently involved in a study of another investigational product for similar&#xD;
             purpose or has been in the previous 90 days;&#xD;
&#xD;
          -  Has any contraindications for MRI;&#xD;
&#xD;
          -  Is a ward of the state, prisoner, or transient.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>60 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Beth Esterl</last_name>
    <role>Study Director</role>
    <affiliation>AlloSource</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Claire McFadyen</last_name>
    <phone>720-484-2452</phone>
    <email>cmcfadyen@allosource.org</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Beth Esterl</last_name>
    <phone>720-873-4700</phone>
    <email>eesterl@allosource.org</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Midwest Orthopaedics at Rush</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60612</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kavita Ahuja</last_name>
      <phone>224-229-2988</phone>
      <email>kavita.ahuja@rushortho.com</email>
    </contact>
    <investigator>
      <last_name>Adam B Yanke, M.D., Ph.D</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Kentucky Research Foundation</name>
      <address>
        <city>Lexington</city>
        <state>Kentucky</state>
        <zip>40506</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Austin Stone, MD</last_name>
      <phone>859-218-3065</phone>
    </contact>
    <contact_backup>
      <last_name>Caitlin Conley, PhD</last_name>
      <phone>(859) 257-1939</phone>
    </contact_backup>
    <investigator>
      <last_name>Austin Stone, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Beacon Orthopaedics &amp; Sports Medicine</name>
      <address>
        <city>Cincinnati</city>
        <state>Ohio</state>
        <zip>45247</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>David Argo, MD</last_name>
      <phone>888-773-4353</phone>
      <email>dargo@beaconortho.com</email>
    </contact>
    <contact_backup>
      <last_name>Daniele Schum</last_name>
      <phone>513-354-7796</phone>
      <email>dschum@beaconortho.com</email>
    </contact_backup>
    <investigator>
      <last_name>David Argo, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Wisconsin-Madison</name>
      <address>
        <city>Madison</city>
        <state>Wisconsin</state>
        <zip>53705</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Deb Brauer, MS, JD</last_name>
      <phone>608-263-3596</phone>
      <email>brauer@ortho.wisc.edu</email>
    </contact>
    <investigator>
      <last_name>Brian Walczak, DO</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>November 2021</verification_date>
  <study_first_submitted>March 12, 2019</study_first_submitted>
  <study_first_submitted_qc>March 12, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">March 13, 2019</study_first_posted>
  <last_update_submitted>November 12, 2021</last_update_submitted>
  <last_update_submitted_qc>November 12, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">November 15, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Cartilage</keyword>
  <keyword>Cartilage Injury</keyword>
  <keyword>Cartilage Repair</keyword>
  <keyword>Cartilage Damage</keyword>
  <keyword>Cartilage Lesion</keyword>
  <keyword>Cartilage Defect</keyword>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

